The relation between free serotonin in plasma, serotonin in platelets, and the type of serotonin transporter in carcinoid tumor patients, patients using SSRI, and healthy controls.

The relation between free serotonin in plasma, serotonin in platelets, and the genotype of the serotonin transporter in carcinoid tumor patients, patients using selective serotonin reuptake inhibitors, and healthy controls.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON24450

Enrollment

105

Registered

2012-04-10

Start date

2011-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In English: carcinoid tumor, SSRI, selective serotonin reuptake inhibitor, serotonin, plasma, platelets, serotonin transporter. Nederlands: carcinoïd tumor, SSRI, selectieve serotonine heropname remmers, serotonine, plasma, bloedplaatjes, serotonine transporter

Interventions

No intervention: At one time point 24mL EDTA blood will be obtained from the patient.

Eligibility

Inclusion criteria

Inclusion criteria: Ethics: 1. Approval of the METC UMCG; 2. Written informed consent. Participants: 1. Healthy men or women; 2. Patients with a metastasized carcinoid tumor, that produces serotonin; 3. Patients with a depression or anxiety disorder, which use selective serotonin reuptake inhibitors: A. The diagnosis is based on the judgement of the patient's current doctor; B. The depression/anxiety disorder can be present or in remission; C. Treatment with SSRI should be at least 6 weeks, and the dose should be suitable (citalopram 20mg; escitalopram 10mg; fluvoxamine 100mg; fluoxetine 20mg; paroxetine 20mg; sertraline 50mg).

Exclusion criteria

Exclusion criteria: 1. The use of medication that interferes with the serotonin metabolism or serotonin reuptake (exception: use of SSRI in patients with depression/anxiety disorder), for example aspirin, psychofarmaca (other than SSRI (TCA, MAO-inhibitors, mirtazapine, bupropion, venlafaxine, duloxetine), anxiolytics, antipsychotics, and anticonvulsants; 2. Drug abuse (8 weeks prior to inclusion); 3. Alcohol abuse (8 weeks prior to inclusion: females: >14 glasses a week, males: >21 glasses a week); 4. Consumption of walnuts or bananas 48 hours prior to obtaining of blood sample.

Design outcomes

Primary

Measure	Time frame
Analyzing whether there is a difference in the concentration dopamine and serotonin in the plasma and platelets of carcinoid tumor patients, patients using SSRI, and healthy controls.	—

Secondary

Measure	Time frame
Analyzing whether the concentration free serotonin in plasma, and the ratio free serotonin/serotonin in platelets is determined by the genotype of the serotonin transporter.	—

Contacts

Public ContactW.H.A. Jong, de

University Medical Center Groningen CMC IV, Y2.119, EA61 Postbus 30001

w.h.a.de.jong@umcg.nl+31 (0)50 3617015

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)